CNBC

Tempus Founder and CEO, Eric Lefkofsky, discusses how generative AI is more impactful in healthcare diagnostics

Feb 17, 2025
Media Coverage

Related content

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

2026-08-24

Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications

2026-08-04

Tempus Reports Second Quarter 2026 Results

2026-07-30